User:MeredithGitre/Altogen Biosystems
 | This is a draft article. It is a work in progress open to editing by anyone. Please ensure core content policies are met before publishing it as a live Wikipedia article. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL Last edited by Bearcat (talk | contribs) 5 years ago. (Update) |
| Company type | Private |
|---|---|
| Industry | Life Science Biotechnology |
| Headquarters | Las Vegas, Nevada, United States |
| Products | Transfection reagents, |
| Website | www.altogen.com |
Altogen Biosystems is a life science company that specializes in manufacturing transfection reagents [1], with a focus on in vitro siRNA delivery and RNAi applications.[2][3]
Company Profile[edit]
Altogen Biosystems began as a company focusing on non-viral methods of transfection. The company began to experiment with a variety of chemical reagents used to deliver nucleic acids into cells, and eventually started to optimize reagents for specific cell lines.[4] Currently, the company is investing into research pertaining to siRNA delivery and RNAi optimization in cell lines that are difficult to transfect.[5]
In 2017, Altogen Biosystems was named as one of the principal players in the transfection technology market by QY Research.[6]
Products[edit]
Altogen Biosystems has developed an array of optimized transfection reagents [7], and offers custom life science research services at its GLP-compliant laboratory.[8] The company's transfection reagents are meant to help deliver compounds into cells through chemical means; reagents with lipids, nanoparticles, and PEGylated liposomes can allow compounds to enter a cell through the cell membrane.[9] The company also offers RNAi research services that optimize the conditions for RNA interference in chosen cell lines.[10]
References[edit]
- ^ Macron, Doug (8 October 2009). "Reagent Shop Altogen Begins Looking to Apply Technologies to Therapeutic siRNA Delivery". Genomeweb. Retrieved 29 January 2018.
- ^ Blow, Nathan (13 December 2007). "Small RNAs: Delivering the future". Nature. 450: 1117–1120. doi:10.1038/4501117a.
- ^ "Preclinical Contract Research Studies". GHP Magazine: 14–15. February 2017.
- ^ Genetic Engineering and Biotechnology News: Volume 28, Issues 11-21. Gen Pub. 2008. p. 32.
- ^ Roberts, Josh P. (12 August 2014). "Primary Cells Pose No Problem with These Transfection Tools". BioCompare. Retrieved 29 January 2018.
- ^ Ghule, Ajinkya (9 October 2017). "Global Transfection Technologies Market 2017- Bio-Rad, Polyplus Transfection, MaxCyte". Retrieved 29 January 2018.
- ^ "New Products Focus: RNAi" (PDF). Science. 330 (6011): 1700. 17 December 2010. doi:10.1126/science.330.6011.1700-a.
- ^ "Pancreas-targeted siRNA In Vivo Transfection Kit from Altogen Biosystems". BioSpace. 6 March 2012. Retrieved 29 January 2018.
- ^ United States application US20150240262A1, Wenxin Wang & Abhay Pandit, "Polymer synthesis", assigned to National University of Ireland Galway
- ^ Smith, Caitlin (23 February 2009). "siRNA Transfection Tools". BioCompare. Retrieved 29 January 2018.